All In MedTech

FDA Clearance Tracker · P200029-S011

TheraSphere

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 10, 2026

Approved

Time to decision

508 days

Received Sep 20, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P200029-S011
Device name
TheraSphere
Applicant location
Marborough, MA
Received
Sep 20, 2024
Decided
Feb 10, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P200029

Device type

Device class
Class III

Every decision under product code NAW

FDA's approval statement

As written in FDA's record.

TheraSphere are indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.

Source documents

Other decisions for Boston Scientific Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.